Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease
Identifieur interne :
003459 ( PascalFrancis/Corpus );
précédent :
003458;
suivant :
003460
Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease
Auteurs : R. Inzelberg ;
P. Nisipeanu ;
M. J. Rabey ;
A. D. KorczynSource :
-
Movement disorders [ 0885-3185 ] ; 1995.
RBID : Pascal:95-0525342
Descripteurs français
English descriptors
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 10 |
|---|
| A06 | | | | @2 5 |
|---|
| A08 | 01 | 1 | ENG | @1 Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease |
|---|
| A11 | 01 | 1 | | @1 INZELBERG (R.) |
|---|
| A11 | 02 | 1 | | @1 NISIPEANU (P.) |
|---|
| A11 | 03 | 1 | | @1 RABEY (M. J.) |
|---|
| A11 | 04 | 1 | | @1 KORCZYN (A. D.) |
|---|
| A14 | 01 | | | @1 Tel-Aviv univ., Sackler fac. medicine @2 Ramat-Aviv 69978 @3 ISR |
|---|
| A20 | | | | @1 604-607 |
|---|
| A21 | | | | @1 1995 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000054563720110 |
|---|
| A44 | | | | @0 0000 |
|---|
| A45 | | | | @0 10 ref. |
|---|
| A47 | 01 | 1 | | @0 95-0525342 |
|---|
| A60 | | | | @1 P |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C02 | 01 | X | | @0 002B02B06 |
|---|
| C03 | 01 | X | FRE | @0 Parkinson maladie @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Parkinson disease @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Parkinson enfermedad @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Cabergoline @2 NK @2 FR @5 04 |
|---|
| C03 | 03 | X | FRE | @0 Agoniste @5 05 |
|---|
| C03 | 03 | X | ENG | @0 Agonist @5 05 |
|---|
| C03 | 03 | X | SPA | @0 Agonista @5 05 |
|---|
| C03 | 04 | X | FRE | @0 Dopamine @2 NK @2 FR @5 06 |
|---|
| C03 | 04 | X | ENG | @0 Dopamine @2 NK @2 FR @5 06 |
|---|
| C03 | 04 | X | SPA | @0 Dopamina @2 NK @2 FR @5 06 |
|---|
| C03 | 05 | X | FRE | @0 Efficacité traitement @5 16 |
|---|
| C03 | 05 | X | ENG | @0 Treatment efficiency @5 16 |
|---|
| C03 | 05 | X | SPA | @0 Eficacia tratamiento @5 16 |
|---|
| C03 | 06 | X | FRE | @0 Traitement @5 17 |
|---|
| C03 | 06 | X | ENG | @0 Treatment @5 17 |
|---|
| C03 | 06 | X | GER | @0 Aufbereiten @5 17 |
|---|
| C03 | 06 | X | SPA | @0 Tratamiento @5 17 |
|---|
| C03 | 07 | X | FRE | @0 Homme @5 20 |
|---|
| C03 | 07 | X | ENG | @0 Human @5 20 |
|---|
| C03 | 07 | X | SPA | @0 Hombre @5 20 |
|---|
| C03 | 08 | X | FRE | @0 Tolérance @5 23 |
|---|
| C03 | 08 | X | ENG | @0 Tolerance @5 23 |
|---|
| C03 | 08 | X | GER | @0 Toleranz @5 23 |
|---|
| C03 | 08 | X | SPA | @0 Tolerancia @5 23 |
|---|
| C03 | 09 | X | FRE | @0 Long terme @5 24 |
|---|
| C03 | 09 | X | ENG | @0 Long term @5 24 |
|---|
| C03 | 09 | X | SPA | @0 Largo plazo @5 24 |
|---|
| C07 | 01 | X | FRE | @0 Système nerveux pathologie @5 37 |
|---|
| C07 | 01 | X | ENG | @0 Nervous system diseases @5 37 |
|---|
| C07 | 01 | X | SPA | @0 Sistema nervioso patología @5 37 |
|---|
| C07 | 02 | X | FRE | @0 Système nerveux central pathologie @5 38 |
|---|
| C07 | 02 | X | ENG | @0 Central nervous system disease @5 38 |
|---|
| C07 | 02 | X | SPA | @0 Sistema nervosio central patología @5 38 |
|---|
| C07 | 03 | X | FRE | @0 Encéphale pathologie @5 39 |
|---|
| C07 | 03 | X | ENG | @0 Cerebral disorder @5 39 |
|---|
| C07 | 03 | X | SPA | @0 Encéfalo patología @5 39 |
|---|
| C07 | 04 | X | FRE | @0 Extrapyramidal syndrome @5 40 |
|---|
| C07 | 04 | X | ENG | @0 Extrapyramidal syndrome @5 40 |
|---|
| C07 | 04 | X | SPA | @0 Extrapiramidal síndrome @5 40 |
|---|
| C07 | 05 | X | FRE | @0 Maladie dégénérative @5 41 |
|---|
| C07 | 05 | X | ENG | @0 Degenerative disease @5 41 |
|---|
| C07 | 05 | X | SPA | @0 Enfermedad degenerativa @5 41 |
|---|
| N21 | | | | @1 296 |
|---|
|
|---|
Format Inist (serveur)
| NO : | PASCAL 95-0525342 INIST |
|---|
| ET : | Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease |
|---|
| AU : | INZELBERG (R.); NISIPEANU (P.); RABEY (M. J.); KORCZYN (A. D.) |
|---|
| AF : | Tel-Aviv univ., Sackler fac. medicine/Ramat-Aviv 69978/Israël |
|---|
| DT : | Publication en série; Niveau analytique |
|---|
| SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1995; Vol. 10; No. 5; Pp. 604-607; Bibl. 10 ref. |
|---|
| LA : | Anglais |
|---|
| CC : | 002B02B06 |
|---|
| FD : | Parkinson maladie; Cabergoline; Agoniste; Dopamine; Efficacité traitement; Traitement; Homme; Tolérance; Long terme |
|---|
| FG : | Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative |
|---|
| ED : | Parkinson disease; Agonist; Dopamine; Treatment efficiency; Treatment; Human; Tolerance; Long term |
|---|
| EG : | Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease |
|---|
| GD : | Aufbereiten; Toleranz |
|---|
| SD : | Parkinson enfermedad; Agonista; Dopamina; Eficacia tratamiento; Tratamiento; Hombre; Tolerancia; Largo plazo |
|---|
| LO : | INIST-20953.354000054563720110 |
|---|
| ID : | 95-0525342 |
|---|
Links to Exploration step
Pascal:95-0525342
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease</title>
<author><name sortKey="Inzelberg, R" sort="Inzelberg, R" uniqKey="Inzelberg R" first="R." last="Inzelberg">R. Inzelberg</name>
<affiliation><inist:fA14 i1="01"><s1>Tel-Aviv univ., Sackler fac. medicine</s1>
<s2>Ramat-Aviv 69978</s2>
<s3>ISR</s3>
</inist:fA14><author><name sortKey="Nisipeanu, P" sort="Nisipeanu, P" uniqKey="Nisipeanu P" first="P." last="Nisipeanu">P. Nisipeanu</name>
</author><author><name sortKey="Rabey, M J" sort="Rabey, M J" uniqKey="Rabey M" first="M. J." last="Rabey">M. J. Rabey</name>
</author><author><name sortKey="Korczyn, A D" sort="Korczyn, A D" uniqKey="Korczyn A" first="A. D." last="Korczyn">A. D. Korczyn</name>
</author><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">95-0525342</idno>
<date when="1995">1995</date>
<idno type="stanalyst">PASCAL 95-0525342 INIST</idno>
<idno type="RBID">Pascal:95-0525342</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003459</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease</title>
<author><name sortKey="Inzelberg, R" sort="Inzelberg, R" uniqKey="Inzelberg R" first="R." last="Inzelberg">R. Inzelberg</name>
<affiliation><inist:fA14 i1="01"><s1>Tel-Aviv univ., Sackler fac. medicine</s1>
<s2>Ramat-Aviv 69978</s2>
<s3>ISR</s3>
</inist:fA14><author><name sortKey="Nisipeanu, P" sort="Nisipeanu, P" uniqKey="Nisipeanu P" first="P." last="Nisipeanu">P. Nisipeanu</name>
</author><author><name sortKey="Rabey, M J" sort="Rabey, M J" uniqKey="Rabey M" first="M. J." last="Rabey">M. J. Rabey</name>
</author><author><name sortKey="Korczyn, A D" sort="Korczyn, A D" uniqKey="Korczyn A" first="A. D." last="Korczyn">A. D. Korczyn</name>
</author><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1995">1995</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Dopamine</term>
<term>Human</term>
<term>Long term</term>
<term>Parkinson disease</term>
<term>Tolerance</term>
<term>Treatment</term>
<term>Treatment efficiency</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Cabergoline</term>
<term>Agoniste</term>
<term>Dopamine</term>
<term>Efficacité traitement</term>
<term>Traitement</term>
<term>Homme</term>
<term>Tolérance</term>
<term>Long terme</term>
</keywords><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA08 i1="01" i2="1" l="ENG"><s1>Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease</s1>
</fA08><fA11 i1="01" i2="1"><s1>INZELBERG (R.)</s1>
</fA11><fA11 i1="02" i2="1"><s1>NISIPEANU (P.)</s1>
</fA11><fA11 i1="03" i2="1"><s1>RABEY (M. J.)</s1>
</fA11><fA11 i1="04" i2="1"><s1>KORCZYN (A. D.)</s1>
</fA11><fA14 i1="01"><s1>Tel-Aviv univ., Sackler fac. medicine</s1>
<s2>Ramat-Aviv 69978</s2>
<s3>ISR</s3>
</fA14><fA20><s1>604-607</s1>
</fA20><fA21><s1>1995</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000054563720110</s5>
</fA43><fA44><s0>0000</s0>
</fA44><fA45><s0>10 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>95-0525342</s0>
</fA47><fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Cabergoline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>05</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Agonist</s0>
<s5>05</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Agonista</s0>
<s5>05</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>16</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>16</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>16</s5>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03><fC03 i1="06" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03><fC03 i1="08" i2="X" l="FRE"><s0>Tolérance</s0>
<s5>23</s5>
</fC03><fC03 i1="08" i2="X" l="ENG"><s0>Tolerance</s0>
<s5>23</s5>
</fC03><fC03 i1="08" i2="X" l="GER"><s0>Toleranz</s0>
<s5>23</s5>
</fC03><fC03 i1="08" i2="X" l="SPA"><s0>Tolerancia</s0>
<s5>23</s5>
</fC03><fC03 i1="09" i2="X" l="FRE"><s0>Long terme</s0>
<s5>24</s5>
</fC03><fC03 i1="09" i2="X" l="ENG"><s0>Long term</s0>
<s5>24</s5>
</fC03><fC03 i1="09" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>24</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07><fN21><s1>296</s1>
</fN21><server><NO>PASCAL 95-0525342 INIST</NO>
<ET>Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease</ET>
<AU>INZELBERG (R.); NISIPEANU (P.); RABEY (M. J.); KORCZYN (A. D.)</AU>
<AF>Tel-Aviv univ., Sackler fac. medicine/Ramat-Aviv 69978/Israël</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1995; Vol. 10; No. 5; Pp. 604-607; Bibl. 10 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Cabergoline; Agoniste; Dopamine; Efficacité traitement; Traitement; Homme; Tolérance; Long terme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Agonist; Dopamine; Treatment efficiency; Treatment; Human; Tolerance; Long term</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<GD>Aufbereiten; Toleranz</GD>
<SD>Parkinson enfermedad; Agonista; Dopamina; Eficacia tratamiento; Tratamiento; Hombre; Tolerancia; Largo plazo</SD>
<LO>INIST-20953.354000054563720110</LO>
<ID>95-0525342</ID>
</server>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003459 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003459 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:95-0525342
|texte= Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
